Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia.
暂无分享,去创建一个
S. Lynch | A. E. El Solh | L. Pineda | Morohunfolu E. Akinnusi | J. Wiener‐Kronish | Kristie R. Szarpa
[1] Mauricio Valencia,et al. Ventilator-associated pneumonia , 2009, Current opinion in critical care.
[2] F. Sutterwala,et al. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome , 2007, The Journal of experimental medicine.
[3] D. Glidden,et al. Increased Plasminogen Activator Inhibitor-1 Concentrations in Bronchoalveolar Lavage Fluids Are Associated with Increased Mortality in a Cohort of Patients with Pseudomonas aeruginosa , 2007, Anesthesiology.
[4] M. Schultz,et al. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: Role of bacterial pathogens* , 2007, Critical care medicine.
[5] R. Ramphal,et al. Neutrophil Elastase, an Innate Immunity Effector Molecule, Represses Flagellin Transcription in Pseudomonas aeruginosa , 2006, Infection and Immunity.
[6] S. McColley,et al. Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.
[7] Nnis System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.
[8] J. Coburn,et al. Characterization of Pseudomonas aeruginosa Exoenzyme S as a Bifunctional Enzyme in J774A.1 Macrophages , 2003, Infection and Immunity.
[9] M. Riese,et al. Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins , 2002, Molecular microbiology.
[10] Anna L Jansson,et al. Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) activities towards small GTPases in vivo. , 2002, The Biochemical journal.
[11] J. Rello,et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2002, Critical Care Medicine.
[12] G. Taylor,et al. Induction of Neutrophil Apoptosis by the Pseudomonas aeruginosa Exotoxin Pyocyanin: A Potential Mechanism of Persistent Infection1 , 2002, The Journal of Immunology.
[13] J. Barbieri,et al. In Vivo Rho GTPase-Activating Protein Activity of Pseudomonas aeruginosa Cytotoxin ExoS , 2002, Infection and Immunity.
[14] N. Shime,et al. Therapeutic Administration of Anti-PcrV F(ab′)2 in Sepsis Associated with Pseudomonas aeruginosa1 , 2001, The Journal of Immunology.
[15] D. Frank,et al. Multiple Domains Are Required for the Toxic Activity of Pseudomonas aeruginosa ExoU , 2001, Journal of bacteriology.
[16] R. Savel,et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. , 2001, The Journal of infectious diseases.
[17] K. Aktories,et al. Pseudomonas aeruginosa ExoT Is a Rho GTPase-Activating Protein , 2000, Infection and Immunity.
[18] U. Ha,et al. Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of exoS. , 2000, Microbiology.
[19] G. Pier,et al. Acquisition of Expression of the Pseudomonas aeruginosa ExoU Cytotoxin Leads to Increased Bacterial Virulence in a Murine Model of Acute Pneumonia and Systemic Spread , 2000, Infection and Immunity.
[20] H. Katus,et al. Decreased apoptosis and increased activation of alveolar neutrophils in bacterial pneumonia. , 2000, Chest.
[21] J. Croizé,et al. Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils , 2000, Infection and Immunity.
[22] K. Aktories,et al. The N-terminal Domain of Pseudomonas aeruginosaExoenzyme S Is a GTPase-activating Protein for Rho GTPases* , 1999, The Journal of Biological Chemistry.
[23] B. Toussaint,et al. Cell Death of Human Polymorphonuclear Neutrophils Induced by a Pseudomonas aeruginosa Cystic Fibrosis Isolate Requires a Functional Type III Secretion System , 1999, Infection and Immunity.
[24] Y. Carmeli,et al. Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents , 1999, Antimicrobial Agents and Chemotherapy.
[25] J. Wiener-Kronish,et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury , 1999, Nature Medicine.
[26] T. Yahr,et al. Biological Effects of Pseudomonas aeruginosa Type III-Secreted Proteins on CHO Cells , 1999, Infection and Immunity.
[27] J. Barbieri,et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Barbieri,et al. Intracellular expression of the ADP‐ribosyltransferase domain of Pseudomonas exoenzyme S is cytotoxic to eukaryotic cells , 1998, Molecular microbiology.
[29] Michael A. Gropper,et al. In Vitro Cellular Toxicity PredictsPseudomonas aeruginosa Virulence in Lung Infections , 1998, Infection and Immunity.
[30] C. Hueck,et al. Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants , 1998, Microbiology and Molecular Biology Reviews.
[31] J. Rello,et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? , 1998, American journal of respiratory and critical care medicine.
[32] J. Engel,et al. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence , 1998, Molecular microbiology.
[33] Lei Zhu,et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury , 1997, Molecular microbiology.
[34] J. Savill,et al. Actin is cleaved during constitutive apoptosis. , 1997, The Biochemical journal.
[35] S. Fleiszig,et al. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S , 1997, Infection and immunity.
[36] T. Yahr,et al. Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway , 1996, Molecular microbiology.
[37] M. Rué,et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] R. Wunderink,et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. , 1996, Chest.
[39] C. Sprung,et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.
[40] J. Pittet,et al. Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury. , 1994, The American journal of physiology.
[41] J. Rello,et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. , 1993, Chest.
[42] P. Montravers,et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. , 1993, The American journal of medicine.
[43] J. Lupski,et al. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. , 1991, Nucleic acids research.
[44] M. Walport,et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. , 1989, The Journal of clinical investigation.
[45] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[46] P. K. Smith,et al. Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.
[47] R. Wenzel,et al. Epidemiology of infections due to Pseudomonas aeruginosa. , 1984, Reviews of infectious diseases.
[48] B. Iglewski,et al. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S , 1984, Infection and immunity.
[49] P. Henson,et al. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages , 1982, The Journal of experimental medicine.
[50] National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.